BiotechTube

Vapendavir + Placebo Oral Tablet

Phase 2Withdrawn
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Rhinovirus

Conditions

Rhinovirus, Upper Respiratory Tract Infection

Trial Timeline

— → —

NCT ID
NCT03024177

About Vapendavir + Placebo Oral Tablet

Vapendavir + Placebo Oral Tablet is a phase 2 stage product being developed by Vaxart for Rhinovirus. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03024177. Target conditions include Rhinovirus, Upper Respiratory Tract Infection.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03024177Phase 2Withdrawn

Competing Products

1 competing product in Rhinovirus

See all competitors
ProductCompanyStageHype Score
BTA798 + PlaceboVaxartPhase 2
44

Other Products from Vaxart

Vapendavir + Vapendavir + PlaceboPhase 2
44
VXA-A1.1 + Fluzone®Phase 2
44
VXA-CoV2-1.1-SPhase 2
44
BTA798 + PlaceboPhase 2
44
40 mg Laninamivir Octanoate + 80 mg Laninamivir Octanoate + PlaceboPhase 2
44